Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects

Ge Li1*, Elaine R. Peskind1,4, Steven P. Millard4, Peter Chi1, Izabela Sokal2, Chang-En Yu3,5, Lynn M. Bekris3,4, Murray A. Raskind1,4, Douglas R. Galasko6, Thomas J. Montine2

1 Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, United States of America; 2 Department of Pathology, University of Washington School of Medicine, Seattle, Washington, United States of America; 3 Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America; 4 Mental Illness Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States of America; 5 Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States of America; 6 Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America.

* E-mail: gli@u.washington.edu

Abstract

Background: Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that is critical to organization of neuronal networks and synaptic plasticity, especially in the hippocampus. We tested hypothesis that reduced CSF BDNF is associated with age-related cognitive decline.

Methodology/Principal Findings, and Conclusions/Significance: CSF concentration of BDNF, Aβ42 and total tau were measured in 128 cognitively normal adults (Normals), 21 patients with Alzheimer’s disease (AD), and nine patients with Mild Cognitive Impairment. Apolipoprotein E and BDNF SNP rs6265 genotype were determined. Neuropsychological tests were performed at baseline for all subjects and at follow-up visits in 50 Normals. CSF BDNF level was lower in AD patients compared to age-matched Normals (p = 0.02). CSF BDNF concentration decreased with age among Normals and was higher in women than men (both p < 0.001). After adjusting for age, gender, education, CSF Aβ42 and total tau, and APOE and BDNF genotypes, lower CSF BDNF concentration was associated poorer immediate and delayed recall at baseline (both p < 0.05) and in follow up of approximately 3 years duration (both p < 0.01).

Conclusions/Significance: Reduced CSF BDNF was associated with age-related cognitive decline, suggesting a potential mechanism that may contribute in part to cognitive decline in older individuals.

Introduction

Age-related cognitive decline is a complex, convergent phenotype likely derived in part from brain senescence and in part from prodromal dementing illnesses, most commonly Alzheimer’s disease (AD). Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that, along with its receptors, is expressed widely in the central nervous system and is critical to organization of neuronal networks and synaptic plasticity, especially in the hippocampus, in a variety of animal models and apparently in humans [1,2]. Although controversy remains, these human data derive mostly from investigations of an allelic variant of BDNF (Val66Met or Met-BDNF), inheritance of which has been associated with poorer cognitive performance in healthy older adults [3], impaired memory in patients with schizophrenia and healthy controls [1,2], abnormal hippocampal activation as assessed by fMRI [2], and an approximately 4% to 11% smaller hippocampal volume as determined by MRI in healthy adult volunteers [3,4]. The mechanisms that underlie these associations of functional and structural differences with inheritance of Met-BDNF are not clear; however, one study has shown diminished depolarization-induced secretion of Met-BDNF compared to Val-BDNF, and failure of Met-BDNF to localize to secretory granules or synapses in transfected neurons [2]. Together, these findings have led to the hypothesis that reduced BDNF secretion is one mechanism of age-related cognitive decline. We are unaware of any published study that has yet tested this hypothesis.

Methods

All procedures were approved by the institutional review boards of the University of Washington; all subjects were recruited from University of Washington Alzheimer’s Disease Research Center and provided written informed consent. Subjects underwent detailed clinical and laboratory evaluation and were classified as no cognitive impairment (Normals), amnestic mild cognitive
impairment (MCI) [5], or probable AD [6]. Inclusion and exclusion criteria, method of CSF collection, and analysis were exactly as previously described [7].

CSF concentration of BDNF, total tau and Aβ42 was measured using an X-MAP-based assay [7]. APOE genotype was determined by a restriction digest method [8]. BDNF SNP rs6265 was genotyped using TaqMan allelic discrimination detection, as previously described [9].

Neuropsychological tests included: (i) Paragraph Recall - a test of declarative memory [10,11]. Paragraphs were modeled after the Logical Memory subtests I and II of the WMS-R [12]. Total score for immediate recall and delayed recall (each with possible range 0–25) were used. (ii) Category Fluency - a test of semantic memory [13]. Total number of unique animals named in 60 seconds was used. (iii) Trail Making Test, Parts A and B - test of ability to adapt to shifting task demands. Time taken to complete Part B (upper bound of 300 sec), a measure of executive function [14], was used.

One-way analysis of variance (ANOVA) was used with post hoc Bonferroni multiple pair-wise comparisons for continuous variables and Fisher’s exact test for categorical variables to assess differences between diagnostic and genetic groups. Linear regression models were used for associations of demographic characteristics with CSF BDNF concentration, and cross-sectional relationships between CSF BDNF concentration and coincident cognitive test performance. Raw scores were used for each test except log-transformed times for Trails B to remove skewness. We used two-stage regression (least squares slope for each test in each individual over time, then weighted regression model with slope as response variable) to assess association of baseline CSF BDNF concentration with subsequent longitudinal changes of cognitive test performance [15]. Weights were based on subjects having different numbers of follow-up visits at different times after baseline. Statistical analyses were performed using S-PLUS version 8.0 [16] and R version 2.7.1 [17].

Results

Age-matched Normals, MCI, and AD

Table 1 depicts demographics and baseline CSF BDNF levels in 128 normal controls (Normals), 9 MCI and 21 AD patients. To compare measures between these three groups after adjusting for age, a subset of the Normals (n = 76) age≥50 years (Older Normals, ON) was used as a comparison group. CSF BDNF level was lower in AD patients compared to ON with a mean difference of 25 pg/ml (post-hoc Bonferroni test, p = 0.02). CSF BDNF level for the nine MCI patients was not different from either group (both p>0.05). The frequencies of Met-BDNF genotype (G/G vs. G/A or A/A) were not different between ON, MCI, and AD subjects (Fisher’s Exact Test p = 0.36). Moreover, CSF BDNF concentration in AD subjects was not different among Met-BDNF genotype G/G, G/A (70%, 217±38 pg/ml), G/A (25%, 214±39 pg/ml), or A/A (5%, 213 pg/ml, n = 1) (F = 0.02, df = 2, p = 0.99).

**Table 1. Subject characteristics and CSF BDNF levels at baseline.**

|                          | Normals | Normals With Follow-up | ON (Normals age≥50) | MCI | AD | p-value (ON, MCI & AD)** |
|--------------------------|---------|------------------------|--------------------|-----|----|--------------------------|
| Number                   | 128     | 50                     | 76                 | 9   | 21 |                         |
| Age, years, mean±SD (Range) | 52±20 (21–100) | 72±9 (41–100) | 67±10 (50–100) | 74±8 (63–82) | 68±10 (52–87) | 0.14 |
| Gender, male %           | 49      | 46                     | 43                 | 67  | 48 | 0.45                     |
| Race, Caucasian %*       | 90      | 90                     | 89                 | 100 | 95 | 0.29                     |
| APOE Genotype, any A4 %* | 30      | 28                     | 35                 | 78  | 65 | 0.004                    |
| BDNF Genotype rs6265 G/A or A/A %* | 40 | 34                     | 39                 | 12  | 30 | 0.36                     |
| Education, years mean±SD* | 16±3   | 16±3                   | 16±3               | 16±3 | 15±3 | 0.33                     |
| BDNF, pg/ml, mean±SD     | 240±33  | 233±35                 | 240±36             | 241±36 | 216±35 | 0.02                     |
| MMSE, mean±SD            | 29±1    | 29±1                   | 29±1               | 28±1 | 20±5 |                         |

ON: Older Normals; MCI: Mild Cognitive Impairment; AD: Alzheimer disease; MMSE: Mini-Mental State Exam.

*Missing Values. Race – 1 (AD), APOE – 2 (one ON, one AD), BDNF Genotype – 4 (two ON, one MCI, one AD). Education – 1 (AD).

**p-value based on one-way ANOVA for continuous variables and Fisher’s exact test for categorical variables. No comparison between groups was performed for MMSE since this test is used for diagnosis.

doi:10.1371/journal.pone.0005424.t001
(Model 1); adjusting for the previous variables as well as concentration of CSF Aβ12 and total tau (biomarkers of latent and prodromal AD [18,19], Model 2); and adjusting for the previous variables as well as presence of APOE ε4 and Met-BDNF (Model 3). There was an association between higher CSF BDNF concentrations and better performance on Paragraph Recall - Delayed that was independent of CSF Aβ12 and total tau concentrations (Model 2) as well as presence of APOE ε4 and Met-BDNF (Model 3); correlation with the Paragraph Recall - Immediate was significant when all predictor variables were in the model (Model 3). An association between lower CSF BDNF and poor performance on Trail Making Test Part B also was observed. There was no significant correlation between CSF BDNF concentration and performance on the Category Fluency test.

**Association between baseline CSF BDNF concentration and longitudinal changes in cognitive performance.** Fifty Normals (27 women), aged 40–100 years (mean±SD = 71.5±8.9) had at least one clinical follow-up visit (mean±SD 4.0±1.1, Range = 2–6) with an average length of follow-up of 3.3 years (SD = 1.2 years, Range = 0.7–5.8 years) (Table 1). Figure 2 shows unadjusted annual changes in cognitive test scores versus baseline CSF BDNF concentration. After adjusting for age, gender, years of education, and baseline test score, lower values of baseline BDNF concentration were significantly associated with greater annual decline in Immediate and Delayed Recall scores on the Paragraph Recall test, and a greater annual decline in the Category Fluency test (Model 4). These relationships were unchanged after further adjusting for baseline CSF Aβ12 and total tau concentrations (Model 5), suggesting that prediction by baseline CSF BDNF concentration for subsequent cognitive changes is independent of preclinical AD. These relationships also were unchanged after further adjusting for presence of APOE ε4 and Met-BDNF (Model 6). All results were unaffected by removing the subject who had the largest annual decline for Immediate Recall, Delayed Recall, and Category Fluency (Figure 2).

**Table 2.** Relationships between baseline CSF BDNF concentration with cross-sectional and longitudinal cognitive performance.

|                         | Cross-sectional (n = 121) | Longitudinal (n = 50) |
|-------------------------|---------------------------|-----------------------|
|                         | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 |
| Paragraph Recall: Immediate Recall | 0.17 (0.11); 0.13 | 0.22 (0.12); 0.06 | 0.26 (0.12); 0.03 | 0.09 (0.04); 0.02 | 0.11 (0.04); 0.01 | 0.13 (0.04); <0.01 |
| Paragraph Recall: Delayed Recall | 0.32 (0.11); <-0.01 | 0.39 (0.11); <-0.01 | 0.43 (0.10); <-0.01 | 0.13 (0.05); <0.01 | 0.13 (0.05); 0.01 | 0.15 (0.05); <0.01 |
| Category Fluency: Animal | -0.08 (0.19); 0.67 | 0.02 (0.19); 0.93 | 0.06 (0.19); 0.73 | 0.16 (0.06); 0.01 | 0.19 (0.06); <0.01 | 0.21 (0.07); <0.01 |
| Log10 Trail Making test: Part B | -0.009 (0.005); 0.07 | -0.013 (0.005); 0.02 | -0.011 (0.005); 0.03 | 0.001 (0.001); 0.42 | -0.002 (0.001); 0.14 | -0.002 (0.001); 0.11 |

Data are: linear regression model coefficient (SE) per10 pg/ml; p-value. **Models 1, 2, and 3:** Cross-sectional relationships between baseline CSF BDNF concentration and coincident cognitive test scores in 121 Normals with baseline neuropsychological testing. Model 1: adjusted for age, gender, and years of education. Model 2: Model 1 plus CSF Aβ12 and total tau concentrations. Model 3: Model 2 plus APOE ε4 (ε4− vs. ε4+) and Met-BDNF genotype (G/G vs. G/A or A/A) (n = 119 because of two missing values for rs6265 genotype). **Models 4, 5 and 6:** Longitudinal relationships between baseline CSF BDNF concentration and subsequent annual change in cognitive test scores for 50 Normals with follow-up evaluation. Model 4: adjusted for age, gender, years of education, and baseline test score. Model 5: Model 4 plus baseline CSF Aβ12 and total tau concentrations. Model 6: Model 5 plus APOE ε4 (ε4− vs. ε4+) and Met-BDNF genotype (G/G vs. G/A or A/A). 

doi:10.1371/journal.pone.0005424.t002
Relationship between BDNF genotype and cognitive performance in the Normals

Among all Normals (n = 119; 2 missing values for genotype), baseline performance on each of the four cognitive tests (Immediate and Delayed Recall, Category Fluency, and Trail Making Part B) did not differ by Met-BDNF genotype (G/G vs. G/A or A/A, all p > 0.05), even after adjusting for age, gender and education in the multiple regression model (all p > 0.05). Similarly, the longitudinal changes in these cognitive performances (n = 50) were not associated with Met-BDNF genotype (all p > 0.05).

Discussion

We made three novel observations in cognitively normal individuals. (i) CSF BDNF decreased across the human life-span in the absence of dementia or MCI and was independent of inheritance of Met-BDNF or the APOE e4 allele. (ii) Women had higher average CSF BDNF concentrations than men. (iii) Lower CSF BDNF concentration was associated strongly with poorer memory and less so with diminished executive function; importantly, these associations were independent of CSF biomarkers of preclinical AD, suggesting that the mechanisms that contribute to early AD and to age-related decline in CSF BDNF might be independent. We must acknowledge that this study has a relatively small sample size and short duration of follow-up and further studies are needed to validate our results.

While ours is the first study of which we are aware to investigate age-related changes in CSF BDNF, other studies have investigated disease-associated changes in CSF BDNF in patients with idiopathic Parkinson disease [7,20] or in patients with AD [7,21,22]. We confirmed that CSF BDNF is further reduced beyond age-related decline in patients with probable AD. CSF and serum BDNF concentrations do not correlate [23]; yet, increased and decreased serum BDNF levels are related to early and late stages, respectively, of AD [24].

The gender difference in CSF BDNF observed in this study is especially interesting, and we speculate that this may be due to hormonal effects. Animal studies have shown that estrogen receptors colocalize to cells that express BDNF and its receptor trkB, and estrogen regulates the expression of BDNF [25]. The relationship between estrogen levels and BDNF expression and secretion, and their potential effect on the cognition in humans requires further studied.

Our data showed that progressive decline in CSF BDNF concentration was a feature of advancing age independent of preclinical AD or dementia, and was associated strongly with
reduced performance in declarative memory tests and less strongly with performance on tests of executive function, perhaps a reflection of the special role of BDNF in hippocampal function. Age-related reduction in CSF BDNF was independent of inheritance of Met-BDNF or APOE e4. Further reduction in CSF BDNF occurred in AD. Our data suggest that reduced secretion of BDNF in the central nervous system is one mechanism that may contribute to age-related cognitive decline.

References

1. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, et al. (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23: 6690–4.

2. Egan MF, Koijma M, Callicott JH, Goldberg TE, Kolachana BS, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257–69.

3. Miyajima F, Oller W, Mayes A, Jackson A, Thacker N, et al. (2008) Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 7: 411–7.

4. Buell JC, Afifi M, Sen S, Gomez-Hassam D, Burneister M, et al. (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59: 812–5.

5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalog EG, et al. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303–8.

6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–44.

7. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, et al. (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129: 326–9.

8. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545–8.

9. Miyajima F, Oller W, Mayes A, Jackson A, Thacker N, et al. (2008) Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 7: 411–7.

10. Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP, et al. (1998) Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy subjects. Biol Psychiatry 59: 812–5.

11. Craft S, Dagogo-Jack SF, Wicheop BV, Murphy C, Nevins RT, et al. (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107: 926–40.

12. Wechsler D, Stone CP (1983) Manual: Wechsler Memory Scale. New York: Psychological Corporation.

13. Gomez RG, White DA (2006) Using verbal fluency to detect very mild dementia of the Alzheimer type. Arch Clin Neuropsychol 21: 717–5.

14. Reitan RW, D (1985) The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press.

15. Milliken JR, Ellland SD (2000) Mixed effect models of longitudinal Alzheimer’s disease: a cautionary note. Stat Med 19: 1617–29.

16. Corporation I, S-PLUS. 2008, Insightful Corporation: seattle, WA.

17. Team R DD C, R. A language and environment for statistical computing. 2008, R Foundation for Statistical Computing: Vienna, Austria.

18. Li G, Sokal I, Quinn JF, Leverenz JB, Brodie M, et al. (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69: 631–9.

19. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343–9.

20. Nagatsu T, Mogi M, Ichinose H, Tozari A (2000) Changes in cytokines and neurotrophins in Parkimson’s disease. J Neural Transm Suppl. pp 277–90.

21. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, et al. (2003) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 133–41; discussion 125–33.

22. Blasko I, Lederer W, Oberhauser H, Walch T, Kemmler G, et al. (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord 21: 9–15.

23. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, et al. (2007) BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41: 387–94.

24. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, et al. (2007) BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41: 387–94.

25. Soltzbrub F, Lewis DK (2006) Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol 27: 404–14.